Alpine Immune Sciences, Inc. (34LA.F)
| Previous close | 59.50 |
| Open | 59.00 |
| Bid | 59.00 x N/A |
| Ask | 60.50 x N/A |
| Day's range | 59.00 - 59.00 |
| 52-week range | 7.75 - 61.00 |
| Volume | |
| Avg. volume | 33 |
| Market cap | 4.093B |
| Beta (5Y monthly) | 0.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Alpine Immune Sciences Reports First Quarter 2024 Financial Results
SEATTLE, May 09, 2024--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024.
- Business Wire
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
SEATTLE, April 10, 2024--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today shared updated clinical data for povetacicept in IgA nephropathy (IgAN) which will be presented as a late breaking poster at the World Congress of Nephrology (WCN) April 13-16, 2024 in Buenos Aires, Argentina.
- Business Wire
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
BOSTON & SEATTLE, April 10, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, today announced that the companies have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share or approximately $4.9 billion in cash. The transaction was unanimously approved by both the Vertex and Alpine Boards of Director
